Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Advances in Head and Neck Cancer Biology and Clinical Management
share announcement

Advances in Head and Neck Cancer Biology and Clinical Management

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (1 August 2021) | Viewed by 10352

Special Issue Editor

Dr. Sidharth V. Puram

E-Mail Website
Collection Editor
1. Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, 4921 Parkview Pl, St. Louis, MO 63110, USA
2. Department of Genetics, Washington University School of Medicine, 4921 Parkview Pl, St. Louis, MO 63110, USA
Interests: intra-tumoral heterogeneity; head and neck cancer; metastasis; treatment resistance; epigenetic and transcriptional regulation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The field of oncology is ever expanding, with research into head and neck cancer rapidly growing by the day. Head and neck cancers are the 6th leading cause of cancer-related death, with significant impact on patients through functional effects on speech, swallowing, taste, and aesthetics. Despite significant advances in surgery, radiation, and chemotherapy, progress in head and neck cancer has been fairly limited. Patients continue to suffer from the persistent challenges of metastasis, treatment failure, and recurrence. Although immunotherapy has significantly influenced the field, success rates are modest and there is significant potential for further research to influence management of these patients. In particular, challenges both from the perspective of basic biology as well as clinical decision-making persist.

This Topical Collection in Cancers (IF 6.639) will highlight studies that attempt to advance head and neck cancer research in new directions, both biologically and clinically. We ask for articles covering both basic, pre-clinical, and clinical aspects of this disease that are particularly innovative in their approach, methodology, perspective, or translational impact. In particular, research that would have an impact outside of head and neck and potentially inform our approach to other tumors will be particular welcomed—that is, submissions should ideally reach and impact beyond field-specific knowledge or interest. Our hope is to establish a Topical Collection which highlights frontiers in the field, identifying opportunities for major new directions and future research.

Dr. Sidharth V. Puram
Collection Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • head and neck cancer
  • signaling
  • genomics
  • informatics
  • clinical outcomes

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 1897 KiB  
Article
Nutritional Status as a Predictive Biomarker for Immunotherapy Outcomes in Advanced Head and Neck Cancer
by Meytal Guller, Matthew Herberg, Neha Amin, Hosam Alkhatib, Christopher Maroun, Evan Wu, Hailey Allen, Ying Zheng, Christine Gourin, Peter Vosler, Marietta Tan, Wayne Koch, David Eisele, Tanguy Seiwert, Carole Fakhry, Drew Pardoll, Gangcai Zhu and Rajarsi Mandal
Cancers 2021, 13(22), 5772; https://doi.org/10.3390/cancers13225772 - 18 Nov 2021
Cited by 23 | Viewed by 2532
Abstract
The association between pretreatment nutritional status and immunotherapy response in patients with advanced head and neck cancer is unclear. We retrospectively analyzed a cohort of 99 patients who underwent treatment with anti-PD-1 or anti-CTLA-4 antibodies (or both) for stage IV HNSCC between 2014 [...] Read more.
The association between pretreatment nutritional status and immunotherapy response in patients with advanced head and neck cancer is unclear. We retrospectively analyzed a cohort of 99 patients who underwent treatment with anti-PD-1 or anti-CTLA-4 antibodies (or both) for stage IV HNSCC between 2014 and 2020 at the Johns Hopkins Hospital. Patient demographics and clinical characteristics were retrieved from electronic medical records. Baseline prognostic nutritional index (PNI) scores and pretreatment body mass index (BMI) trends were calculated. Associations between PNI and BMI were correlated with overall survival (OS), progression-free survival (PFS), and immunotherapy response. In univariate analysis, there was a significant correlation between OS and PFS with baseline PNI (OS: HR: 0.464; 95% CI: 0.265–0.814; PFS: p = 0.007 and HR: 0.525; 95% CI: 0.341–0.808; p = 0.003). Poor OS was also associated with a greater decrease in pretreatment BMI trend (HR: 0.42; 95% CI: 0.229–0.77; p = 0.005). In multivariate analysis, baseline PNI but not BMI trend was significantly associated with OS and PFS (OS: log (HR) = −0.79, CI: −1.6, −0.03, p = 0.041; PFS: log (HR) = −0.78, CI: −1.4, −0.18, p = 0.011). In conclusion, poor pretreatment nutritional status is associated with negative post-immunotherapy outcomes. Full article
(This article belongs to the Special Issue Advances in Head and Neck Cancer Biology and Clinical Management)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

15 pages, 1076 KiB  
Review
A Contemporary Review of Molecular Therapeutic Targets for Adenoid Cystic Carcinoma
by Lauren E. Miller, Vivienne Au, Tara E. Mokhtari, Deborah Goss, Daniel L. Faden and Mark A. Varvares
Cancers 2022, 14(4), 992; https://doi.org/10.3390/cancers14040992 - 16 Feb 2022
Cited by 19 | Viewed by 4170
Abstract
ACC is a rare malignant tumor of the salivary glands. In this contemporary review, we explore advances in identification of targetable alterations and clinical trials testing these druggable targets. A search of relevant articles and abstracts from national meetings and three databases, including [...] Read more.
ACC is a rare malignant tumor of the salivary glands. In this contemporary review, we explore advances in identification of targetable alterations and clinical trials testing these druggable targets. A search of relevant articles and abstracts from national meetings and three databases, including PubMed, Medline, and Web of Science, was performed. Following keyword search analysis and double peer review of abstracts to ensure appropriate fit, a total of 55 manuscripts were included in this review detailing advances in molecular targets for ACC. The most researched pathway associated with ACC is the MYB–NFIB translocation, found to lead to dysregulation of critical cellular pathways and thought to be a fundamental driver in a subset of ACC disease pathogenesis. Other notable molecular targets that have been studied include the cKIT receptor, the EGFR pathway, and NOTCH1, all with limited efficacy in clinical trials. The ongoing investigation of molecular abnormalities underpinning ACC that may be responsible for carcinogenesis is critical to identifying and developing novel targeted therapies. Full article
(This article belongs to the Special Issue Advances in Head and Neck Cancer Biology and Clinical Management)
►▼ Show Figures

Figure 1

35 pages, 2209 KiB  
Review
Head and Neck Cancers Are Not Alike When Tarred with the Same Brush: An Epigenetic Perspective from the Cancerization Field to Prognosis
by Diego Camuzi, Tatiana de Almeida Simão, Fernando Dias, Luis Felipe Ribeiro Pinto and Sheila Coelho Soares-Lima
Cancers 2021, 13(22), 5630; https://doi.org/10.3390/cancers13225630 - 11 Nov 2021
Cited by 11 | Viewed by 2586
Abstract
Head and neck squamous cell carcinomas (HNSCC) are among the ten most frequent types of cancer worldwide and, despite all efforts, are still diagnosed at late stages and show poor overall survival. Furthermore, HNSCC patients often experience relapses and the development of second [...] Read more.
Head and neck squamous cell carcinomas (HNSCC) are among the ten most frequent types of cancer worldwide and, despite all efforts, are still diagnosed at late stages and show poor overall survival. Furthermore, HNSCC patients often experience relapses and the development of second primary tumors, as a consequence of the field cancerization process. Therefore, a better comprehension of the molecular mechanisms involved in HNSCC development and progression may enable diagnosis anticipation and provide valuable tools for prediction of prognosis and response to therapy. However, the different biological behavior of these tumors depending on the affected anatomical site and risk factor exposure, as well as the high genetic heterogeneity observed in HNSCC are major obstacles in this pursue. In this context, epigenetic alterations have been shown to be common in HNSCC, to discriminate the tumor anatomical subsites, to be responsive to risk factor exposure, and show promising results in biomarker development. Based on this, this review brings together the current knowledge on alterations of DNA methylation and microRNA expression in HNSCC natural history, focusing on how they contribute to each step of the process and on their applicability as biomarkers of exposure, HNSCC development, progression, and response to therapy. Full article
(This article belongs to the Special Issue Advances in Head and Neck Cancer Biology and Clinical Management)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop